Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer benefits beyond glycaemic control.
- GLP-1 RAs are associated with anti-inflammatory effects.
- These agents may have anti-atherogenic properties, which could impact cardiovascular health.
- There is potential for immunomodulatory effects in individuals with systemic lupus erythematosus (SLE).
- Metabolic dysfunction, cardiovascular disease, and chronic inflammation are prevalent in SLE patients.
Simplified